134 related articles for article (PubMed ID: 37713046)
1. Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators.
Song X; Wang P; Feng R; Chetry M; Li E; Wu X; Liu Z; Liao S; Lin J
Clin Transl Oncol; 2024 Feb; 26(2):389-397. PubMed ID: 37713046
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
4. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer.
Kerin EP; Davey MG; McLaughlin RP; Sweeney KJ; Barry MK; Malone CM; Elwahab SA; Lowery AJ; Kerin MJ
Breast; 2022 Dec; 66():227-235. PubMed ID: 36335747
[TBL] [Abstract][Full Text] [Related]
9. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
10. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
13. Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients.
Tamaki K; Ishida T; Tamaki N; Kamada Y; Uehara K; Miyashita M; Amari M; Tadano-Sato A; Takahashi Y; Watanabe M; McNamara K; Ohuchi N; Sasano H
Breast Cancer; 2014 May; 21(3):325-33. PubMed ID: 22782361
[TBL] [Abstract][Full Text] [Related]
14. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
Qiao W; Guo W; Liu Q; Guo X; Deng M
Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
[TBL] [Abstract][Full Text] [Related]
15. Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus.
Duan F; Song C; Ma Y; Jiang K; Xu F; Bi X; Huang J; Hong R; Huang Z; Lu Q; Yuan Z; Wang S; Xia W
Drug Des Devel Ther; 2021; 15():3463-3473. PubMed ID: 34408400
[TBL] [Abstract][Full Text] [Related]
16. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Chen L; Kong X; Huang S; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
Front Immunol; 2022; 13():831848. PubMed ID: 35320931
[TBL] [Abstract][Full Text] [Related]
17. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
Bense RD; Sotiriou C; Piccart-Gebhart MJ; Haanen JBAG; van Vugt MATM; de Vries EGE; Schröder CP; Fehrmann RSN
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27737921
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
19. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
